8.18
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
What analysts say about Cullinan Therapeutics Inc. stockBreakneck growth rates - PrintWeekIndia
When is the best time to buy Cullinan Therapeutics Inc. stockFree Stock Chart Pattern Guide - jammulinksnews.com
What drives Cullinan Therapeutics Inc. stock priceSignificant capital appreciation - PrintWeekIndia
Cullinan Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com
Is Cullinan Therapeutics Inc. a good long term investmentUnbelievable profit margins - Autocar Professional
Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan
Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha
How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Disc Medicine Appoints Nadim Ahmed To Board - citybiz
Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times
Cullinan Therapeutics shares rise 1.36% intraday after CEO Nadim Ahmed appointed to Disc Medicine's Board of Directors. - AInvest
We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener
Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):